W hite adipose tissue evolved as a mechanism to store fuel in the form of triglycerides. It was initially found surrounding the viscera in the peritoneal cavity, but later in evolution, major depots of adipose tissue were located in subcutaneous sites. 1 The development of large subcutaneous depots allows the appropriate compartmentalization of lipids, preventing their accumulation in other tissues. Studies in animal models suggest that adipose tissue expansion requires angiogenesis. [2] [3] [4] Conditions that impair angiogenesis block adipose tissue accumulation, 5, 6 and proangiogenic stromal cells and elevated plasma and adipose tissue levels of proangiogenic factors have been observed in obese rodents 7-10 and in human patients. 11, 12 However, the specific role of angiogenesis in human obesity has not been defined.
Clinical Perspective on p 194
Both subcutaneous and visceral depots retain extraordinary growth potential throughout adult life, 13 but there is signifi-cant, heritable variation in the relative size of these depots. 14 Subcutaneous and visceral adipose tissues differ in their cellular composition, their molecular properties, and their role in regulation of the whole body metabolism. 15, 16 Although expansion of both subcutaneous and visceral adipose tissue contributes to metabolic disease, subcutaneous adipose tissue is considered to be a weaker risk factor 14, 17 and in some cases has been reported to have a protective effect. 18 The mechanisms that determine the degree of expansion of each depot in response to excess caloric intake and their relationship with metabolic disease risk are unknown.
We and others have previously found that when embedded in fibrin/thrombin clots 19 or in Matrigel, 20 small fragments of mouse adipose tissue develop angiogenic sprouts similar to those seen in aortic ring angiogenesis assays. 21, 22 The extent of sprouting is higher in explants from mice undergoing adipose tissue expansion, such as in response to hyperphagia or treatment with thiazolidinediones, 20 suggesting that this assay reflects angiogenic growth in vivo. In the present study, we used this assay to study angiogenesis from human adipose tissue and its relationship with adipose tissue capillary density, mass, and individual metabolic parameters. Our results demonstrate that the capillary density and angiogenic capacity of visceral adipose tissue are lower than those of subcutaneous tissue but that subcutaneous capillary density and angiogenic capacity decrease with morbid obesity. Our data suggest that variation in angiogenic capacity may influence adipose tissue expandability and may be a risk factor in metabolic disease.
Methods

Research Design
Adipose tissue was obtained from adults undergoing Roux-en-Y gastric bypass surgery or from healthy volunteers with a stable body mass index (BMI) of 25 to 35.5. Gastric bypass patients had a BMI of Ն36 and qualified under published National Institutes of Health guidelines for the treatment of morbid obesity. Samples of subcutaneous and visceral adipose tissue were taken from the lower abdominal wall and greater omentum, respectively. Subcutaneous adipose tissue from normal volunteers was collected from the lower abdominal area by needle aspiration with a 14-gauge needle. 23 The inner diameter of this needle is 1.6 mm, and therefore Ϸ1-mm fragments could be obtained without disrupting tissue architecture. Informed consents were required and signed before inclusion into the study, and protocols were approved by the University of Massachusetts Medical School institutional review board. Patient characteristics are summarized in Table 1 .
Ex Vivo Angiogenesis Assay of Adipose Tissue
Freshly harvested samples of human adipose tissue were placed in sterile EBM-2 media (Lonza). After removal of fibrotic tissue and obvious vasculature, the tissue was cut into Ϸ1-mm 3 pieces, each of which was embedded in an individual well of a 96-well plate containing 40 L of growth factor-depleted Matrigel (BD Discovery Labware). The size of each piece varied in the range of 1Ϯ0.5 mm 3 , and preliminary data did not indicate a correlation between the extent of capillary branch formation and explant size within this range. Nevertheless, to eliminate a possible effect of explant size, values for each patient represent the average number of capillary branches formed by each of Ϸ50 independent explants. Wells were filled with 200 L of EBM-2 media supplemented with endothelial growth factors (EGM-2 MV) (Lonza), and half of the media was replaced every second day. The number of branches forming around the periphery (defined as a minimum of 3 cells forming a branch structure) was counted at days 7 and 14 in culture, at ϫ100 magnification, by 2 independent investigators. In addition, the percentage of explants growing capillary branches out of the total number of explants embedded was recorded.
Analysis of Adipose Tissue Capillary Density
Adipose tissue samples were fixed in 4% formaldehyde (Ted Pella, Inc), embedded in paraffin, cut into 4-m sections, and stained with rabbit anti-human von Willebrand factor (vWF) (1:200) or mouse anti-human CD31 (clone JC70A; 1:100) obtained from Dako (Glostrup, Denmark). Indirect immunohistochemistry was performed with a Dako labeled streptavidin biotin-horseradish peroxidase kit. The numbers of positive capillary lumens per area were counted under ϫ400 magnification, in at least 3 independent sections, with at least 10 fields per section for each adipose tissue sample, by 2 independent investigators who did not know the origin of the samples.
Immunofluorescent Staining and Analysis
Adipose tissue explants embedded in Matrigel in 35-mm glassbottom culture dishes (MatTek Corporation) were fixed in 4% formaldehyde (Ted Pella, Inc) and stained with mouse anti-human antibodies to the following: endothelial nitric oxide synthase (BD PharMingen, San Diego, CA), CD31, CD34, ␣-smooth muscle actin (Dako), or rabbit anti-human vWF (Biocare). The total and immunopositive cells per field were counted in at least 15 randomly chosen fields at ϫ200 magnification.
Western Blotting
Western blotting was performed with the use of mouse anti-human CD31 (Dako, clone JC70A; 1:200), rabbit anti-human angiopoietinlike protein 4 (ANGPTL4) (Zymed; 1:1000), and ␤-actin antibody (Sigma, St Louis, MO, 1:1000) and visualized with Western Lightning Chemiluminiscent (PerkinElmer Life Science).
Affymetrix Microarray Analysis
Total RNA from matched visceral and subcutaneous samples from 11 patients was isolated with the use of TRIzol. Affymetrix protocols were followed for the preparation of cRNA, which was hybridized to HG-U133v2 chips. Raw expression data collected from an Affymetrix HP GeneArrayScanner were normalized across all 22 data sets with the use of the RMA algorithm. A linear model approach 24 was used to determine differentially expressed genes. Derived P values were adjusted for multiple testing with the method of Benjamini and Hochberg. 25 Statistical significance was defined as being differentially expressed with an adjusted P value of Ͻ0.05. Hierarchical agglomerative clustering was done in R with the single-linkage method. The distance matrix was calculated with the Canberra metric. For gene set enrichment analysis, probe identities were mapped on Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways with the Bioconductor annotation library hgu133plus2.db, version 2.0.1, for the Affymetrix Human Genome U133 Plus 2.0 Array. Differentially expressed probe lists were shrunk to the sublist that mapped to KEGG pathways. These were compared with all the probe sets on the U133 Plus 2.0 Array that mapped to a KEGG pathway to evaluate enrichment with the use of the R package compdiagTools.
Statistical Analysis
For normally distributed data (verified by a P value Ͻ0.05 with the D'Agostino-Pearson normality test), 2-tailed, unpaired Student t tests were used to compare the means collected from 2 distinct groups of patients, and 2-tailed paired Student t tests were used to compare subcutaneous and visceral adipose tissue from the same Values are means, with range for each parameter shown in parentheses. Two-tailed Student t test was used to determine statistically significant differences between gastric bypass surgery and needle biopsy populations.
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patients. For small sample sizes for which normality could not be established, the nonparametric 2-tailed Wilcoxon matched-pairs test was employed. Linear regression analysis was performed with the use of GraphPad Prism, and results are indicated in each figure.
Results
Differences in Angiogenic Capacity Between Adipose Tissue Depots
Approximately 4 days after they are embedded, cells emerge from adipose tissue explants and form an arborized network of capillary branches ( Figure 1 and Movie I in the online-only Data Supplement). The majority of these cells are endothelial ( Figure 2 ), as indicated by markers CD31 (present in 83% to 93% of cells), endothelial nitric oxide synthase (in 93% to 99% of cells), CD34 (in 71% to 86% of cells), and vWF (in 86% to 94% of cells). Smooth muscle actin was seen in 5% to 10% of cells typically found surrounding endothelial branches ( Figure 2E ) and probably represents parricides. Sample pairs of subcutaneous and visceral adipose tissue were obtained from 26 patients undergoing gastric bypass surgery ( Figure 3 and individual patient data in Table I in the online-only Data Supplement). Explants from both depots readily developed capillary branches ( Figure 3A ). The percentage of visceral adipose tissue explants developing capillary branches was lower than that from subcutaneous tissue, but this difference did not reach statistical significance in a paired analysis (76Ϯ5% versus 69Ϯ6% of explants from subcutaneous versus visceral adipose tissue, respectively [meanϮSEM at day 14]; Pϭ0.388). However, a significant difference in the number of capillary branches formed from subcutaneous compared with visceral explants was observed at days 7 and 14 of culture ( Figure 3B ). The rate of growth ex vivo, assessed by the difference in the number of capillary branches between days 14 and 7, was also higher in explants from subcutaneous compared with visceral adipose tissue ( Figure 3B ). To compare the differences in growth with the initial capillary density of the tissues, we performed immunohistochemical analysis on samples from 7 representative patients ( Figure 4 and individual patients marked by asterisks in Table I in the online-only Data Supplement) with the use of the endothelial cell markers vWF ( Figure 4A ) or CD31 ( Figure 4B ). Irrespective of the marker analyzed, subcutaneous adipose tissue capillary density was significantly higher compared with visceral tissue when normalized to the number of adipocytes ( Figure 4C ), which tended to be larger in subcutaneous tissue ( Figure 4D ). In addition, the level of CD31 was higher in subcutaneous adipose tissue than in visceral tissue when analyzed by Western blotting ( Figure 4E ). Thus, capillary density per adipocyte is higher in subcutaneous than in visceral adipose tissue. However, the increased angiogenic growth of subcutaneous adipose tissue ex vivo cannot be explained completely by higher initial capillary density because it persisted when the number of angiogenic branches was normalized to the initial capillary density ( Figure 4F ). These results indicate that subcutaneous adipose tissue has higher capillary density per adipocyte in vivo and higher capacity for angiogenic growth ex vivo compared with visceral adipose tissue.
To further explore whether differences in angiogenic capacity between subcutaneous and visceral adipose tissue depots reflect differences in adipose tissue in vivo, we analyzed the expression of angiogenesis-related genes. Subcutaneous and visceral adipose tissue samples from 11 nondiabetic, insulin-sensitive (Homeostasis Minimal Assessment Index of Insulin Resistance [HOMA-IR] Ͻ2.3) individuals who were not under any prescription medication (Table 1) were studied. The 54 612 probes in the HG-U133v2 Affymetrix chip revealed the presence of 10 652 gene transcripts expressed in both visceral and subcuta-neous adipose tissue. Of these, 2014 probes were differentially expressed with a P value Ͻ0.001, and 483 of these 2014 were differentially expressed by 2.8-fold (Table II in the online-only Data Supplement). A single-link hierarchical method applied to this gene set produced 2 main clusters ( Figure 5A ), which were further analyzed by mapping their members on the KEGG pathways. These genes were significantly enriched in pathways for extracellular matrix receptor interaction, cell adhesion, and tight junction pathways, likely originating from endothelial cells within the tissue ( Table 2 ). In addition, TBX15 and NR2F1, developmental genes previously found to be differentially expressed between subcutaneous and visceral adipose tissue in mice and humans, 26 were among the genes found in this data set ( Table II in the online-only Data Supplement).
Of the genes present in subcutaneous and visceral adipose tissue, 242 have been associated with the gene ontology term angiogenesis. Of these, 53 differed by Ն1.5-fold in expression level with a P value Ͻ0.05 (Table III in cutaneous adipose tissue was found to express significantly higher levels of ANGPTL4, a factor induced in response to hypoxia and implicated in the regulation of lipid metabolism. [27] [28] [29] [30] We have previously shown ANGPTL4 to be proangiogenic in the context of adipose tissue and to correlate with enhanced angiogenesis in mice treated with rosiglitazone. 20 We find that the increase in mRNA levels of ANGPTL4 in subcutaneous adipose tissue is also seen at the protein levels ( Figure  5B ). Thus, this difference between visceral and subcutaneous human adipose tissue could explain at least in part the observed difference in angiogenic capacity between these depots.
Impaired Capillary Density and Angiogenic Capacity With Increasing BMI
To determine whether angiogenesis of subcutaneous adipose tissue varies with the demand for adipose tissue expansion, we compared tissue from overweight (BMI 25 to 35.5) versus obese (BMI 36 to 59) individuals. No significant difference in angiogenic capacity between these groups was seen at day 7 of culture, but at day 14 the number of branches growing in samples from obese individuals was only 65% of that seen in samples from overweight individuals ( Figure 6A ). When all data were pooled, encompassing a BMI range between 25 and 59, a negative correlation between BMI and capillary branch formation at day 14 ( Figure 6B ) and between the rate of growth ex vivo, calculated as the difference between days 14 and 7 ( Figure 6C) , was apparent. These results suggest that angiogenic capacity of subcutaneous adipose tissue decreases with morbid obesity.
We then analyzed whether the decrease in angiogenic capacity ex vivo reflected the capillary density of the originating tissue (Figure 7) . Subcutaneous adipose tissue from individuals with BMI Ͼ36 had less than half of the amount of capillaries per unit area compared with tissue from individuals with a BMI between 25 and 35.5 (Figure 7A through  7C) . Although the higher BMI was also associated with larger adipocytes ( Figure 7D) , differences in capillary density remained significant after normalization to adipocyte number ( Figure 7E ). Thus, subcutaneous adipose tissue from individuals with BMI Ͼ36 is less vascularized than that from individuals with lower BMI and displays decreased angiogenic capacity ex vivo, possibly as a reflection of a lower initial capillary density.
One of the reasons for which increasing BMI might correlate with insufficient capillary density and angiogenic capacity could be related to decreased insulin sensitivity that occurs in obesity. To address this question, we analyzed the relationship between insulin sensitivity and angiogenic capacity in subcutaneous and visceral adipose tissue from 26 gastric bypass surgery patients ( Figure 8 ). As expected, a positive correlation between HOMA-IR and BMI was seen within the gastric bypass patient population ( Figure 8A) , as well as when overweight and obese individuals were pooled together (not illustrated). HOMA-IR correlated negatively with subcutaneous angiogenic capacity in the gastric bypass patient population ( Figure 8B ) as well as in the pooled population (not illustrated). Interestingly, no significant correlation was seen between HOMA-IR and visceral angiogenic capacity ( Figure 8C ). The negative correlation between HOMA-IR and subcutaneous angiogenic capacity was maintained in a subgroup analysis of samples of gastric bypass surgery patients for which capillary density and adipocyte size had been determined previously ( Figure 8D and 8E ). In this randomly chosen subgroup, there was no significant correlation between angiogenic capacity ex vivo and subcutaneous capillary density ( Figure 8F ), suggesting that impaired angiogenic capacity in morbidly obese individuals is better explained by qualitative changes associated with insulin resistance than by differences in capillary density of the originating tissue.
Discussion
One of the most remarkable features of adipose tissue is its capacity to expand in a nonneoplastic manner. Impaired adipose tissue expandability, such as that occurring in lipodystophy, leads to ectopic accumulation of lipids in liver and muscle, insulin resistance, and metabolic disease. 31 Expandability depends on angiogenesis, but the underlying mechanisms of this process in adipose tissue are largely unknown. The method described here allows an accurate and reproducible measurement of new capillary branch formation from human adipose tissue. An advantage of this assay compared with others, such as the chick chorioallantoic membrane model, 32 is that the human tissue is the sole source of cells, and therefore differences observed result exclusively from properties inherent to this tissue. Two findings were made with this approach. First, we found that subcutaneous adipose tissue has a higher capillary density per adipocyte and higher angiogenic growth capacity compared with visceral tissue. Because a higher angiogenic capacity was seen even after normalization to initial capillary density, these results suggest the existence of qualitative differences in angiogenic expandability between subcutaneous and visceral adipose tissue that are revealed ex vivo. Consistent with this view is the finding that the expression of multiple genes involved in angiogenesis varies significantly among these tissues. At least 1 factor previously shown to be proangiogenic in an adipose tissue- specific context, ANGPTL4, 20 is expressed at higher levels in human subcutaneous adipose tissue. Further studies of the role of ANGPTL4, as well as of additional proangiogenic and antiangiogenic genes differentially expressed between subcutaneous and visceral adipose tissue, will be necessary to define the molecular basis for their differing angiogenic capacity.
The mechanism that determines subcutaneous and visceral adipose tissue angiogenic capacity may underlie important physiological differences between these depots. One of these differences is that, whereas expansion of subcutaneous adipose tissue is associated with protection from metabolic disease, 18 expansion of visceral adipose tissue is not. Indeed, the risk of diabetes mellitus and coronary artery disease correlates strongly with relative visceral adiposity rather than with BMI per se. 14, 17 The mechanisms responsible for this risk are not clear; the results shown here suggest that expanding visceral adipose tissue may not be as well vascularized, potentially leading to hypoxia, impaired secretion of adipokines, 33 and inflammation, 34 traits that are associated with visceral adipose tissue and risk of metabolic disease.
The second finding made in this study is that capillary density and angiogenic potential of subcutaneous adipose tissue decrease with increasing BMI. These results are consistent with the recent report of capillary dropout and lower oxygen tension in subcutaneous adipose tissue from obese individuals. 35 Capillary density and angiogenic potential of subcutaneous adipose tissue decrease to a similar extent between overweight (BMI Ͻ36) and obese (BMI Ͼ36) individuals, and therefore decreased angiogenic potential ex vivo might only reflect initial lower capillary density rather than a qualitative decline in expandability between these populations. Indeed, the negative correlation between subcutaneous angiogenic capacity and BMI was surprising because our previous studies in hyperphagic mice demonstrated increased angiogenic capacity with increased adiposity. 20 A difference between these studies, however, is that the human population studied here compares overweight with morbidly obese individuals, whereas the previous study compared lean with overweight mice. Thus, it is possible that angiogenic capacity increases during the transition of lean to overweight but is unable to continue to increase proportionally to adipocyte size and/or number during the progression to extreme obesity. However, the finding that within morbidly obese individuals the impairment in subcutaneous angiogenic growth ex vivo does not correlate with decreased capillary density of the originating tissue suggests that qualitative alterations in angiogenic capacity may also accompany extreme obesity. In any case, the data suggest that in morbid obesity, subcutaneous angiogenesis is insufficient to achieve a level of vascularization appropriate for the expanded tissue.
The negative correlation between subcutaneous angiogenic capacity and BMI could be due to the metabolic alterations that accompany obesity. Consistent with this view is the finding that subcutaneous angiogenic capacity negatively correlates with the increased insulin resistance seen between overweight and obese individuals (not shown) and within morbidly obese individuals undergoing gastric bypass sur- gery (Figure 8 ). One possibility is that production of proangiogenic factors by adipocytes may be compromised by insulin resistance. 36 Whereas adipocyte-derived proangiogenic factors such as leptin 37 increase with adipose tissue mass, other adipocyte-secreted factors such as adiponectin decrease in response to increased cell size or stress. 38 Further studies on the molecular mechanisms that drive and limit adipose tissue angiogenesis and their sensitivity to insulin should provide answers to these questions. A decreased angiogenic capacity in morbid obesity could be a physiologically protective mechanism as a way to limit the increase in adiposity because expansion of adipose tissue is blocked by antiangiogenic drugs. 39 Studies to characterize the relationship between adipocyte growth, insulin sensitivity, and adipose tissue angiogenesis within the spectrum of lean to obese states in humans will be necessary to answer these questions. and visceral angiogenic growth (E) in a subgroup of the patients (nϭ8) analyzed in A, B, and C. F, Linear regression analysis between capillary density of the originating tissue and angiogenic growth in the same subpopulation. P values for each analysis are shown. r 2 values are shown for those cases in which statistical significance was found. Data for each patient can be found in Table I in the online-only Data Supplement. 
Sources of Funding
